Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment.

Is RXRX or ASND more profitable?

Ascendis Pharma A/S has a net margin of -130.33% compared to Recursion Pharmaceuticals' net margin of -579.52%. Ascendis Pharma A/S's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-579.52%	-76.56%	-55.68%
Ascendis Pharma A/S	-130.33%	N/A	-48.77%

Which has better earnings and valuation, RXRX or ASND?

Recursion Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$64.60M	26.76	-$328.07M	-$1.53	-3.94
Ascendis Pharma A/S	$327.43M	25.26	-$521.07M	-$8.08	-16.88

Do insiders & institutionals have more ownership in RXRX or ASND?

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer RXRX or ASND?

Ascendis Pharma A/S received 411 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 66.52% of users gave Ascendis Pharma A/S an outperform vote while only 56.00% of users gave Recursion Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Recursion Pharmaceuticals	Outperform Votes 28 56.00%	Underperform Votes 22 44.00%
Ascendis Pharma A/S	Outperform Votes 439 66.52%	Underperform Votes 221 33.48%

Which has more volatility & risk, RXRX or ASND?

Recursion Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.

Do analysts prefer RXRX or ASND?

Recursion Pharmaceuticals currently has a consensus target price of $9.25, indicating a potential upside of 53.40%. Ascendis Pharma A/S has a consensus target price of $191.77, indicating a potential upside of 40.61%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92

Does the media favor RXRX or ASND?

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 12 mentions for Recursion Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.92 beat Recursion Pharmaceuticals' score of 0.41 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Recursion Pharmaceuticals on 11 of the 18 factors compared between the two stocks.